Natixis Advisors’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $41M | Buy |
180,927
+58,447
| +48% | +$10.4M | 0.05% | 342 |
|
|
2026
Q1 | $21.1M | Buy |
122,480
+8,123
| +7% | +$1.51M | 0.03% | 476 |
|
|
2025
Q4 | $22.8M | Buy |
114,357
+9,397
| +9% | +$1.7M | 0.03% | 452 |
|
|
2025
Q3 | $16.4M | Buy |
104,960
+20,050
| +24% | +$3.18M | 0.02% | 535 |
|
|
2025
Q2 | $12.9M | Sell |
84,910
-138
| -0.2% | -$18.4K | 0.02% | 602 |
|
|
2025
Q1 | $12.8M | Buy |
85,048
+6,609
| +8% | +$1.11M | 0.02% | 578 |
|
|
2024
Q4 | $14.5M | Sell |
78,439
-5,704
| -7% | -$1.1M | 0.03% | 543 |
|
|
2024
Q3 | $16.6M | Sell |
84,143
-4,310
| -5% | -$896K | 0.03% | 497 |
|
|
2024
Q2 | $18.3M | Buy |
88,453
+9,664
| +12% | +$2.19M | 0.04% | 410 |
|
|
2024
Q1 | $21.3M | Buy |
78,789
+11,934
| +18% | +$2.85M | 0.05% | 370 |
|
|
2023
Q4 | $15.8M | Buy |
66,855
+6,913
| +12% | +$1.36M | 0.04% | 425 |
|
|
2023
Q3 | $11.7M | Buy |
59,942
+8,903
| +17% | +$1.83M | 0.04% | 460 |
|
|
2023
Q2 | $10.7M | Buy |
51,039
+13,592
| +36% | +$2.7M | 0.03% | 502 |
|
|
2023
Q1 | $7.56M | Buy |
37,447
+3,017
| +9% | +$684K | 0.03% | 587 |
|
|
2022
Q4 | $7.5M | Buy |
34,430
+4,493
| +15% | +$981K | 0.03% | 554 |
|
|
2022
Q3 | $5.89M | Buy |
29,937
+1,974
| +7% | +$426K | 0.02% | 584 |
|
|
2022
Q2 | $5.98M | Buy |
27,963
+1,193
| +4% | +$292K | 0.03% | 597 |
|
|
2022
Q1 | $7.6M | Buy |
26,770
+5,007
| +23% | +$1.54M | 0.03% | 550 |
|
|
2021
Q4 | $8.2M | Sell |
21,763
-2,147
| -9% | -$834K | 0.03% | 521 |
|
|
2021
Q3 | $9.87M | Sell |
23,910
-2,262
| -9% | -$939K | 0.04% | 426 |
|
|
2021
Q2 | $9.68M | Buy |
26,172
+465
| +2% | +$155K | 0.05% | 419 |
|
|
2021
Q1 | $7.45M | Sell |
25,707
-160
| -0.6% | -$44.5K | 0.04% | 465 |
|
|
2020
Q4 | $6.46M | Sell |
25,867
-15,392
| -37% | -$3.67M | 0.04% | 472 |
|
|
2020
Q3 | $9.34M | Sell |
41,259
-3,185
| -7% | -$661K | 0.06% | 340 |
|
|
2020
Q2 | $7.75M | Sell |
44,444
-1,950
| -4% | -$311K | 0.05% | 385 |
|
|
2020
Q1 | $5.86M | Buy |
46,394
+10,576
| +30% | +$1.59M | 0.05% | 411 |
|
|
2019
Q4 | $5.47M | Buy |
35,818
+4,748
| +15% | +$657K | 0.04% | 497 |
|
|
2019
Q3 | $4.11M | Buy |
31,070
+7,434
| +31% | +$997K | 0.03% | 542 |
|
|
2019
Q2 | $3.35M | Sell |
23,636
-23
| -0.1% | -$3.12K | 0.03% | 595 |
|
|
2019
Q1 | $3.44M | Buy |
23,659
+616
| +3% | +$80.9K | 0.03% | 565 |
|
|
2018
Q4 | $2.61M | Buy |
23,043
+1,543
| +7% | +$193K | 0.03% | 619 |
|
|
2018
Q3 | $2.89M | Buy |
21,500
+947
| +5% | +$117K | 0.03% | 658 |
|
|
2018
Q2 | $2.31M | Buy |
20,553
+2,414
| +13% | +$261K | 0.02% | 719 |
|
|
2018
Q1 | $1.94M | Buy |
18,139
+1,943
| +12% | +$209K | 0.02% | 754 |
|
|
2017
Q4 | $1.77M | Buy |
16,196
+1,366
| +9% | +$149K | 0.02% | 740 |
|
|
2017
Q3 | $1.6M | Buy |
+14,830
| New | +$1.52M | 0.02% | 771 |
|
|
2014
Q3 | – | Sell |
-4,598
| Closed | -$246K | – | 1049 |
|
|
2014
Q2 | $246K | Buy |
4,598
+450
| +11% | +$24.7K | ﹤0.01% | 1217 |
|
|
2014
Q1 | $250K | Buy |
+4,148
| New | +$242K | ﹤0.01% | 1136 |
|
Other funds holding CRL
AI
Natixis Advisors's CRL Position: Q2 2026 in Review
Natixis Advisors increased its Charles River Laboratories (CRL) stake by 48% in Q2 2026, buying an estimated $10.4M and bringing the position to 180,927 shares worth $41M. The position accounts for 0.05% of the portfolio, ranked #342.
Natixis Advisors first reported a position in CRL in Q1 2014 and has held it in 38 quarters since. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Natixis Advisors held 180,927 shares of Charles River Laboratories worth $41M as of Q2 2026.
- Natixis Advisors bought 58,447 Charles River Laboratories shares in Q2 2026, an estimated $10.4M.
- Charles River Laboratories made up 0.05% of Natixis Advisors's portfolio in Q2 2026, its #342 holding.
- Natixis Advisors first reported a position in Charles River Laboratories in Q1 2014 and has held it in 38 quarters since.
- 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.